Reuters: Company News
Abbvie to record $4 bln impairment charges on Stemcentrx assets – Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy. …
